SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Ikena Oncology, Inc. IKNA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Ikena Oncology, Inc. (IKNA) is a Biotechnology company in the Healthcare sector, currently trading at $17.16. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is IKNA = $1 (-92.2% upside).

Net income is $52M (loss), growing at +6.3%/yr. Net profit margin is 0% (thin). Gross margin is 88.9% (+1.9 pp trend).

Balance sheet: total debt is $0 against $76M equity (Debt-to-Equity (D/E) ratio 0, conservative). Debt-to-assets is 0%. Total assets: $83M.

Analyst outlook: 4 / 5 analysts rate IKNA as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 52/100 (Partial), Future 58/100 (Partial), Income ?/100 (Fail).

$1.33

▼ 92.25% Downside

Average Price Target

The 12-month price target for Ikena Oncology, Inc. is $1.33.

IKNA SharesGrow Score Overview

52/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 10/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 52/100

Gross margin is + market cap

FUTURE 58/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IKNA

IKNA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $1, implying -94.2% from the current price $17. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

IKNA: -70.7%/yr revenue is, +6.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet IKNA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is N/A. Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

IKNA: Gross margin is 88.9% (+1.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.

View details →

Analyst outlook: 4 / 5 analysts rate IKNA as buy (80%). Analyst consensus target is $1 (-94.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.36-23.28

Volume457.26K

Avg Volume (30D)18K

Market Cap$718.82M

Beta (1Y)0.50

Share Statistics

IPO Date2021-03-26

Employees10

CEOMark Manfredi

Financial Highlights & Ratios

EBITDA$-48.45M

Net Income$-52.4M

Operating Income$-48.45M

Total Cash$75.79M

Net Debt$-34.97M

Total Assets$82.81M

Analyst Forecast

1Y Price Target$1.33

Target High$1.33

Target Low$1.33

Upside-92.2%

Rating ConsensusBuy

Analysts Covering5

Buy 80% Hold 20% Sell 0%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS45175G1085

Price Chart

IKNA

Ikena Oncology, Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

1.36 52WK RANGE 23.28

People Also View

Kymera Therapeutics, Inc.

Edgewise Therapeutics, Inc.

Stoke Therapeutics, Inc.

Nurix Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

Design Therapeutics, Inc.

Eliem Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message